All In Biotech

Drug Trial Radar · NCT04330690

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)

Last checked: Nov 19, 2026Latest source record: Oct 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 2,900 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,900

Planned (sponsor's estimate)

Start

Mar 18, 2020

Primary completion

Mar 10, 2024

Study completion May 18, 2024

Sponsor

Lead sponsor
Sunnybrook Health Sciences CentreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AbbVie; Apotex Inc.; World Health Organization; University of British Columbia; Arch Biopartners Inc.
First posted
Apr 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an adaptive, randomized, open-label, controlled clinical trial, in collaboration with countries around the world through the World Health Organization.

Conditions

  • COVID-19

Interventions

  • ArtesunateDrug

    2.4 mg/kg at 0 hours, 12 hours, 24 hours, and then daily for a total of 7 days plus standard of care

  • ImatinibDrug

    400 mg enterally daily for 14 days plus standard of care

  • InfliximabDrug

    5 mg/kg IV given one time, over 2 hours plus standard of care

  • DexamethasoneDrug

    6 mg IV/oral for a further five days, followed by a five day taper of 4 mg x 2 days and 2 mg x 3 days, for a total 20 day steroid course. If randomized to standard of care, discontinue the corticosteroid on day 10

  • LSALT PeptideDrug

    5 mg , 2 hour IV infusion once daily for up to 14 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Randomization WHO- MortalityTime frame: 28 days
  2. Randomization Dex- Clinical StatusTime frame: 28 days
  3. Randomization LSALT- Respiratory supportTime frame: 28 days

Locations

53 sites in 1 country. Site status is shown where the registry gives one.

  • Peter Lougheed Centre

    Calgary, Alberta, Canada

  • Foothills Medical Centre

    Calgary, Alberta, Canada

  • Rockyview General Hospital

    Calgary, Alberta, Canada

  • South Health Campus

    Calgary, Alberta, Canada

  • Royal Alexandra Hospital

    Edmonton, Alberta, Canada

  • Misericordia Community Hospital

    Edmonton, Alberta, Canada

  • University of Alberta Hopsital

    Edmonton, Alberta, Canada

  • Grey Nuns Community Hospital

    Edmonton, Alberta, Canada

  • Interior Health Royal Inland Hospital

    Kamloops, British Columbia, Canada

  • Lions Gate Hospital

    North Vancouver, British Columbia, Canada

  • Richmond Hospital

    Richmond, British Columbia, Canada

  • Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia

    Vancouver, British Columbia, Canada

  • St Paul's Hospital

    Vancouver, British Columbia, Canada

  • Island Health - Royal Jubilee Hospital

    Victoria, British Columbia, Canada

  • Island Health - Victoria General Hospital

    Victoria, British Columbia, Canada

  • Island Health - Nanaimo Regional General Hospital

    Victoria, British Columbia, Canada

  • St. Boniface Hospital

    Winnipeg, Manitoba, Canada

  • Health Sciences Centre

    Winnipeg, Manitoba, Canada

  • Grace General Hospital

    Winnipeg, Manitoba, Canada

  • Eastern Regional Health Authority

    St. John's, Newfoundland and Labrador, Canada

  • Nova Scotia Health Authority

    Halifax, Nova Scotia, Canada

  • Royal Victoria Regional Health Centre

    Barrie, Ontario, Canada

  • William Osler Health System - Brampton Civic Hospital

    Brampton, Ontario, Canada

  • William Osler Health System - Etobicoke General Hospital

    Etobicoke, Ontario, Canada

  • St. Joseph's Healthcare Hamilton

    Hamilton, Ontario, Canada

  • St.Joseph's Health Care

    London, Ontario, Canada

  • University Hospital

    London, Ontario, Canada

  • Victoria Hospital

    London, Ontario, Canada

  • Markham Stouffville Hospital

    Markham, Ontario, Canada

  • Trillium Health Partners -Mississauga Site

    Mississauga, Ontario, Canada

  • Trillium Health Partners-Credit Valley Hospital

    Mississauga, Ontario, Canada

  • The Ottawa Hospital - General Campus

    Ottawa, Ontario, Canada

  • Hôpital Montfort

    Ottawa, Ontario, Canada

  • The Ottawa Hospital - Civic Campus

    Ottawa, Ontario, Canada

  • Queensway Carleton Hospital

    Ottawa, Ontario, Canada

  • Niagara Health

    Saint Catharines, Ontario, Canada

  • Scarborough Health Network - Centenary Hospital

    Scarborough Village, Ontario, Canada

  • Scarborough Health Network - General Hospital

    Scarborough Village, Ontario, Canada

  • Scarborough Health Network - Birchmount Hospital

    Scarborough Village, Ontario, Canada

  • Thunder Bay Regional Health Sciences Centre

    Thunder Bay, Ontario, Canada

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.